Free Trial
NASDAQ:MOLN

Molecular Partners (MOLN) Stock Price, News & Analysis

Molecular Partners logo
$4.03 -0.05 (-1.23%)
As of 11:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Molecular Partners Stock (NASDAQ:MOLN)

Key Stats

Today's Range
$4.08
$4.08
50-Day Range
$3.54
$5.03
52-Week Range
$3.36
$12.70
Volume
533 shs
Average Volume
21,016 shs
Market Capitalization
$162.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00
Consensus Rating
Strong Buy

Company Overview

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
47th Percentile Overall Score

MOLN MarketRank™: 

Molecular Partners scored higher than 47% of companies evaluated by MarketBeat, and ranked 626th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Molecular Partners has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Molecular Partners has only been the subject of 1 research reports in the past 90 days.

  • Read more about Molecular Partners' stock forecast and price target.
  • Earnings Growth

    Earnings for Molecular Partners are expected to decrease in the coming year, from ($1.93) to ($2.08) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Molecular Partners is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Molecular Partners is -1.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Molecular Partners has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Molecular Partners' valuation and earnings.
  • Percentage of Shares Shorted

    0.10% of the float of Molecular Partners has been sold short.
  • Short Interest Ratio / Days to Cover

    Molecular Partners has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Molecular Partners has recently decreased by 1.79%, indicating that investor sentiment is improving.
  • Dividend Yield

    Molecular Partners does not currently pay a dividend.

  • Dividend Growth

    Molecular Partners does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.10% of the float of Molecular Partners has been sold short.
  • Short Interest Ratio / Days to Cover

    Molecular Partners has a short interest ratio ("days to cover") of 5.5.
  • Change versus previous month

    Short interest in Molecular Partners has recently decreased by 1.79%, indicating that investor sentiment is improving.
  • News Sentiment

    Molecular Partners has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Molecular Partners this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for MOLN on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Molecular Partners insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 5.93% of the stock of Molecular Partners is held by insiders.

  • Percentage Held by Institutions

    Only 26.55% of the stock of Molecular Partners is held by institutions.

  • Read more about Molecular Partners' insider trading history.
Receive MOLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter.

MOLN Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
See More Headlines

MOLN Stock Analysis - Frequently Asked Questions

Molecular Partners' stock was trading at $4.75 at the beginning of the year. Since then, MOLN stock has decreased by 14.1% and is now trading at $4.08.
View the best growth stocks for 2025 here
.

Molecular Partners AG (NASDAQ:MOLN) posted its quarterly earnings results on Thursday, March, 6th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.11. Molecular Partners had a negative net margin of 1,043.01% and a negative trailing twelve-month return on equity of 39.31%.
Read the conference call transcript
.

Molecular Partners (MOLN) raised $81 million in an initial public offering (IPO) on Wednesday, June 16th 2021. The company issued 3,000,000 shares at a price of $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets served as the underwriters for the IPO and Kempen & Co. was co-manager.

Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Molecular Partners investors own include PayPal (PYPL), Pfizer (PFE), NVIDIA (NVDA), Advanced Micro Devices (AMD), Robinhood Markets (HOOD), Taiwan Semiconductor Manufacturing (TSM) and Adobe (ADBE).

Company Calendar

Last Earnings
3/06/2025
Today
5/05/2025
Next Earnings (Estimated)
5/15/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MOLN
Fax
N/A
Employees
180
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$12.00
High Stock Price Target
$12.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+194.1%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-69,040,000.00
Net Margins
-1,043.01%
Pretax Margin
-1,043.08%

Debt

Sales & Book Value

Annual Sales
$4.97 million
Price / Cash Flow
N/A
Book Value
$5.41 per share
Price / Book
0.75

Miscellaneous

Free Float
37,969,000
Market Cap
$164.73 million
Optionable
Not Optionable
Beta
1.16
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (NASDAQ:MOLN) was last updated on 5/5/2025 by MarketBeat.com Staff
From Our Partners